As of 2024-12-12, the EV/EBITDA ratio of Finch Therapeutics Group Inc (FNCH) is -0.14. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FNCH's latest enterprise value is 2.09 mil USD. FNCH's TTM EBITDA according to its financial statements is -15.40 mil USD. Dividing these 2 quantities gives us the above FNCH EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.1x - 16.5x | 15.0x |
| Forward P/E multiples | 15.0x - 17.7x | 15.8x |
| Fair Price | (21.40) - (23.57) | (21.87) |
| Upside | -1288.7% - -1409.3% | -1315.1% |
| Date | EV/EBITDA |
| 2024-12-11 | -6.64 |
| 2024-12-10 | -6.64 |
| 2024-12-09 | -6.68 |
| 2024-12-06 | -6.34 |
| 2024-12-05 | -6.65 |
| 2024-12-04 | -6.65 |
| 2024-12-03 | -6.89 |
| 2024-12-02 | -6.65 |
| 2024-11-29 | -6.81 |
| 2024-11-27 | -6.81 |
| 2024-11-26 | -6.71 |
| 2024-11-25 | -6.74 |
| 2024-11-22 | -6.84 |
| 2024-11-21 | -6.45 |
| 2024-11-20 | -6.45 |
| 2024-11-19 | -6.42 |
| 2024-11-18 | -6.27 |
| 2024-11-15 | -6.29 |
| 2024-11-14 | -6.81 |
| 2024-11-13 | -6.32 |
| 2024-11-12 | -6.48 |
| 2024-11-11 | -6.61 |
| 2024-11-08 | -6.68 |
| 2024-11-07 | -6.48 |
| 2024-11-06 | -6.81 |
| 2024-11-05 | -6.84 |
| 2024-11-04 | -6.78 |
| 2024-11-01 | -6.91 |
| 2024-10-31 | -6.81 |
| 2024-10-30 | -6.74 |
| 2024-10-29 | -6.48 |
| 2024-10-28 | -6.65 |
| 2024-10-25 | -6.78 |
| 2024-10-24 | -6.81 |
| 2024-10-23 | -6.81 |
| 2024-10-22 | -6.91 |
| 2024-10-21 | -6.99 |
| 2024-10-18 | -6.84 |
| 2024-10-17 | -6.84 |
| 2024-10-16 | -6.84 |
| 2024-10-15 | -6.81 |
| 2024-10-14 | -6.58 |
| 2024-10-11 | -6.48 |
| 2024-10-10 | -6.48 |
| 2024-10-09 | -6.48 |
| 2024-10-08 | -6.48 |
| 2024-10-07 | -6.48 |
| 2024-10-04 | -6.61 |
| 2024-10-03 | -6.68 |
| 2024-10-02 | -6.74 |